Download PDF
Semin Thromb Hemost 2023; 49(03): 255-271
DOI: 10.1055/s-0042-1758821
Review Article

Antiplatelet Therapy in Coronary Artery Disease: Now and Then

Maximilian Tscharre
1   Department of Internal Medicine, Cardiology and Nephrology, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria
2   Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
,
Thomas Gremmel
2   Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
3   Department of Internal Medicine I, Cardiology and Intensive Care Medicine, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria
4   Institute of Antithrombotic Therapy in Cardiovascular Disease, Karl Landsteiner Society, St. Pölten, Austria
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Cardiovascular disease, particularly coronary artery disease (CAD), remains the leading cause of mortality and morbidity in industrialized countries. Platelet activation and aggregation at the site of endothelial injury play a key role in the processes ultimately resulting in thrombus formation with vessel occlusion and subsequent end-organ damage. Consequently, antiplatelet therapy has become a mainstay in the pharmacological treatment of CAD. Several drug classes have been developed over the last decades and a broad armamentarium of antiplatelet agents is currently available. This review portrays the evolution of antiplatelet therapy, and provides an overview on previous and current antiplatelet drugs and strategies.

Keywords

Coronary artery disease - antiplatelet therapy - aspirin - P2Y12 inhibitors - glycoprotein Ilb/Illa inhibitors - protease-activated receptor 1 antagonists


Publication History

Article published online:
01 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 World Health Organization. WHO World Health Statistics 2018: Monitoring health for the SDGs. WHO [Internet] 2018. Accessed November 11, 2022 at: http://www.who.int/gho/publications/world_health_statistics/2018/en/
    PubMedGoogle Scholar
  • 2 Gremmel T, Frelinger III AL, Michelson AD. Platelet physiology. Semin Thromb Hemost 2016; 42 (03) 191-204
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Quick AJ. Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci 1966; 252 (03) 265-269
    CrossrefPubMedGoogle Scholar
  • 4 Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967; 2 (7514): 495-497
    CrossrefPubMedGoogle Scholar
  • 5 Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971; 231 (25) 235-237
    CrossrefPubMedGoogle Scholar
  • 6 Hamberg M, Samuelsson B. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc Natl Acad Sci U S A 1973; 70 (03) 899-903
    CrossrefPubMedGoogle Scholar
  • 7 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975; 72 (08) 2994-2998
    CrossrefPubMedGoogle Scholar
  • 8 Michelson AD, Bhatt DL. How I use laboratory monitoring of antiplatelet therapy. [Internet] Blood 2017; 130 (06) 713-721
    CrossrefPubMedGoogle Scholar
  • 9 Gremmel T, Michelson AD, Frelinger III AL, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018; 2 (03) 439-449
    CrossrefPubMedGoogle Scholar
  • 10 Gremmel T, Gisslinger B, Gisslinger H, Panzer S. Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count. [Internet] Transl Res 2018; 200: 35-42
    CrossrefPubMedGoogle Scholar
  • 11 Elwood PC, Cochrane AL, Burr ML. et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974; 1 (5905): 436-440
    CrossrefPubMedGoogle Scholar
  • 12 Desborough MJR, Keeling DM. The aspirin story - from willow to wonder drug. Br J Haematol 2017; 177 (05) 674-683
    CrossrefPubMedGoogle Scholar
  • 13 Randomised Trial of Intravenous Streptokinase. Oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988 332. 349-360
    PubMedGoogle Scholar
  • 14 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86
    CrossrefPubMedGoogle Scholar
  • 15 Baigent C, Blackwell L, Collins R. et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-1860
    CrossrefPubMedGoogle Scholar
  • 16 Gaziano JM, Brotons C, Coppolecchia R. et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392 (10152): 1036-1046
    Google Scholar
  • 17 McNeil JJ, Woods RL, Nelson MR. et al; ASPREE Investigator Group. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 2018; 379 (16) 1499-1508
    CrossrefPubMedGoogle Scholar
  • 18 Bowman L, Mafham M, Wallendszus K. et al; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379 (16) 1529-1539
    Google Scholar
  • 19 Jones WS, Mulder H, Wruck LM. et al; ADAPTABLE Team. Comparative effectiveness of aspirin dosing in cardiovascular disease. [Internet] N Engl J Med 2021; 384 (21) 1981-1990
    CrossrefPubMedGoogle Scholar
  • 20 Tscharre M, Michelson AD, Gremmel T. Novel antiplatelet agents in cardiovascular disease. J Cardiovasc Pharmacol Ther 2020; 25 (03) 191-200
    CrossrefPubMedGoogle Scholar
  • 21 Maffrand J-P. The story of clopidogrel and its predecessor, ticlopidine: could these major antiplatelet and antithrombotic drugs be discovered and developed today?. C R Chim 2012; 15: 737-743
    CrossrefPubMedGoogle Scholar
  • 22 Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. [Internet] Expert Rev Cardiovasc Ther 2007; 5 (01) 45-55
    CrossrefPubMedGoogle Scholar
  • 23 Balsano F, Rizzon P, Violi F. et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. [Internet] Circulation 1990; 82 (01) 17-26
    CrossrefPubMedGoogle Scholar
  • 24 Schömig A, Neumann F-J, Kastrati A. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. [Internet] N Engl J Med 1996; 334 (17) 1084-1089
    CrossrefPubMedGoogle Scholar
  • 25 Urban P, Macaya C, Rupprecht HJ. et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98 (20) 2126-2132
    CrossrefPubMedGoogle Scholar
  • 26 Leon MB, Baim DS, Popma JJ. et al; Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. [Internet] N Engl J Med 1998; 339 (23) 1665-1671
    CrossrefPubMedGoogle Scholar
  • 27 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [Internet]. Lancet 1996; 348 (9038): 1329-1339
    CrossrefPubMedGoogle Scholar
  • 28 Bhatt DL, Fox KAA, Hacke W. et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. [Internet] N Engl J Med 2006; 354 (16) 1706-1717
    CrossrefPubMedGoogle Scholar
  • 29 Valgimigli M, Bueno H, Byrne RA. et al; ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
    CrossrefPubMedGoogle Scholar
  • 30 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502
    CrossrefPubMedGoogle Scholar
  • 31 Mehta SR, Yusuf S, Peters RJ. et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527-533
    CrossrefPubMedGoogle Scholar
  • 32 Steinhubl SR, Berger PB, Mann III JT. et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19) 2411-2420
    CrossrefPubMedGoogle Scholar
  • 33 Sabatine MS, Cannon CP, Gibson CM. et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. [Internet] N Engl J Med 2005; 352 (12) 1179-1189
    CrossrefPubMedGoogle Scholar
  • 34 Mehta SR, Bassand J-P, Chrolavicius S. et al; CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363 (10) 930-942
    CrossrefPubMedGoogle Scholar
  • 35 Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111 (16) 2099-2106
    CrossrefPubMedGoogle Scholar
  • 36 Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. [Internet] Eur Heart J 2009; 30 (16) 1964-1977
    CrossrefPubMedGoogle Scholar
  • 37 Erlinge D, Varenhorst C, Braun OÖ. et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52 (24) 1968-1977
    CrossrefPubMedGoogle Scholar
  • 38 Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010; 9 (02) 154-169
    CrossrefPubMedGoogle Scholar
  • 39 Wiviott SD, Braunwald E, McCabe CH. et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
    CrossrefPubMedGoogle Scholar
  • 40 Wallentin L, Becker RC, Budaj A. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
    CrossrefPubMedGoogle Scholar
  • 41 Roe MT, Armstrong PW, Fox KAA. et al; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. [Internet] N Engl J Med 2012; 367 (14) 1297-1309
    CrossrefPubMedGoogle Scholar
  • 42 Montalescot G, Bolognese L, Dudek D. et al; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. [Internet] N Engl J Med 2013; 369 (11) 999-1010
    CrossrefPubMedGoogle Scholar
  • 43 Montalescot G, van 't Hof AW, Lapostolle F. et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. [Internet] N Engl J Med 2014; 371 (11) 1016-1027
    CrossrefPubMedGoogle Scholar
  • 44 Schüpke S, Neumann FJ, Menichelli M. et al; ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019; 381 (16) 1524-1534
    CrossrefPubMedGoogle Scholar
  • 45 Collet J-P, Thiele H, Barbato E. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020; •••: 2020
    PubMedGoogle Scholar
  • 46 Gimbel M, Qaderdan K, Willemsen L. et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial[Internet]. Lancet 2020; 395 (10233): 1374-1381
    CrossrefPubMedGoogle Scholar
  • 47 Koo BK, Kang J, Park KW. et al; HOST-EXAM investigators. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial [Internet]. Lancet 2021; 397 (10293): 2487-2496
    CrossrefPubMedGoogle Scholar
  • 48 Bhatt DL, Lincoff AM, Gibson CM. et al; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. [Internet] N Engl J Med 2009; 361 (24) 2330-2341
    CrossrefPubMedGoogle Scholar
  • 49 Harrington RA, Stone GW, McNulty S. et al. Platelet inhibition with cangrelor in patients undergoing PCI. [Internet] N Engl J Med 2009; 361 (24) 2318-2329
    CrossrefPubMedGoogle Scholar
  • 50 Bhatt DL, Stone GW, Mahaffey KW. et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368 (14) 1303-1313
    CrossrefPubMedGoogle Scholar
  • 51 Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. [Internet] Thromb Res 2011; 128 (04) 352-357
    CrossrefPubMedGoogle Scholar
  • 52 Gremmel T, Durstberger M, Eichelberger B, Koppensteiner R, Panzer S. Calcium-channel blockers attenuate the antiplatelet effect of clopidogrel. [Internet] Cardiovasc Ther 2015; 33 (05) 264-269
    CrossrefPubMedGoogle Scholar
  • 53 Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. [Internet] Heart 2010; 96 (03) 186-189
    CrossrefPubMedGoogle Scholar
  • 54 Gremmel T, Kopp C, Seidinger D, Koppensteiner R, Steiner S, Panzer S. Impact of diabetes on platelet activation in different manifestations of atherosclerosis. . [Internet] Swiss Med Wkly 2013; 143: w13800
    PubMedGoogle Scholar
  • 55 Lee S, Ay C, Kopp CW, Panzer S, Gremmel T. Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting. [Internet] Cardiovasc Diabetol 2018; 17 (01) 131
    CrossrefPubMedGoogle Scholar
  • 56 Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. [Internet] Transl Res 2013; 161 (05) 421-429
    CrossrefPubMedGoogle Scholar
  • 57 Xhelili E, Eichelberger B, Kopp CW, Koppensteiner R, Panzer S, Gremmel T. The antiplatelet effect of clopidogrel decreases with patient age. [Internet] Angiology 2016; 67 (10) 902-908
    CrossrefPubMedGoogle Scholar
  • 58 Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. [Internet] J Thromb Haemost 2010; 8 (01) 37-42
    CrossrefPubMedGoogle Scholar
  • 59 Gremmel T, Müller M, Steiner S. et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. [Internet] Nephrol Dial Transplant 2013; 28 (08) 2116-2122
    CrossrefPubMedGoogle Scholar
  • 60 Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101 (02) 333-339
    Article in Thieme ConnectPubMedGoogle Scholar
  • 61 Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. [Internet] Thromb Haemost 2011; 106 (02) 211-218
    PubMedGoogle Scholar
  • 62 Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. [Internet] J Am Coll Cardiol 2005; 45 (02) 246-251
    CrossrefPubMedGoogle Scholar
  • 63 Sibbing D, Aradi D, Alexopoulos D. et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv 2019; 12 (16) 1521-1537
    CrossrefPubMedGoogle Scholar
  • 64 Wadowski PP, Pultar J, Weikert C. et al. Comparison of light transmission aggregometry with impedance aggregometry in patients on potent P2Y12 inhibitors. J Cardiovasc Pharmacol Ther 2021; 26 (03) 260-268
    CrossrefPubMedGoogle Scholar
  • 65 Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. [Internet] Int J Cardiol 2012; 160 (02) 109-113
    CrossrefPubMedGoogle Scholar
  • 66 Gremmel T, Eslam RB, Koppensteiner R. et al. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel. . [Internet] Cardiovasc Ther 2013; 31: e40-5
    CrossrefPubMedGoogle Scholar
  • 67 Trenk D, Stone GW, Gawaz M. et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59 (24) 2159-2164
    CrossrefPubMedGoogle Scholar
  • 68 Cayla G, Cuisset T, Silvain J. et al; ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial [Internet]. Lancet 2016; 388 (10055): 2015-2022
    CrossrefPubMedGoogle Scholar
  • 69 Price MJ, Berger PB, Teirstein PS. et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. [Internet] JAMA 2011; 305 (11) 1097-1105
    CrossrefPubMedGoogle Scholar
  • 70 Collet J-P, Cuisset T, Rangé G. et al; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. [Internet] N Engl J Med 2012; 367 (22) 2100-2109
    CrossrefPubMedGoogle Scholar
  • 71 Sibbing D, Aradi D, Jacobshagen C. et al; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial [Internet]. Lancet 2017; 390 (10104): 1747-1757
    CrossrefPubMedGoogle Scholar
  • 72 Kim CJ, Park MW, Kim MC. et al; TALOS-AMI investigators. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet 2021; 398 (10308): 1305-1316
    CrossrefPubMedGoogle Scholar
  • 73 Mauri L, Kereiakes DJ, Yeh RW. et al; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. [Internet] N Engl J Med 2014; 371 (23) 2155-2166
    CrossrefPubMedGoogle Scholar
  • 74 Bonaca MP, Bhatt DL, Cohen M. et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372 (19) 1791-1800
    CrossrefPubMedGoogle Scholar
  • 75 Vranckx P, Valgimigli M, Jüni P. et al; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial [Internet]. Lancet 2018; 392 (10151): 940-949
    CrossrefPubMedGoogle Scholar
  • 76 Mehran R, Baber U, Sharma SK. et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. [Internet] N Engl J Med 2019; 381 (21) 2032-2042
    CrossrefPubMedGoogle Scholar
  • 77 Watanabe H, Domei T, Morimoto T. et al; STOPDAPT-2 Investigators. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019; 321 (24) 2414-2427
    CrossrefPubMedGoogle Scholar
  • 78 Kim BK, Hong SJ, Cho YH. et al; TICO Investigators. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. [Internet] JAMA 2020; 323 (23) 2407-2416
    CrossrefPubMedGoogle Scholar
  • 79 is Watanabe H, Morimoto T, Natsuaki M. et al; STOPDAPT-2 ACS Investigators. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol 2022; 7 (04) 407-417
    CrossrefPubMedGoogle Scholar
  • 80 Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. [Internet] Circulation 2001; 103 (02) 201-206
    CrossrefPubMedGoogle Scholar
  • 81 EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. [Internet] N Engl J Med 1994; 330 (14) 956-961
    CrossrefPubMedGoogle Scholar
  • 82 EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. [Internet] N Engl J Med 1997; 336 (24) 1689-1696
    CrossrefPubMedGoogle Scholar
  • 83 Brener SJ, Barr LA, Burchenal JE. et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. [Internet] Circulation 1998; 98 (08) 734-741
    CrossrefPubMedGoogle Scholar
  • 84 EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade[Internet]. Lancet 1998; 352 (9122): 87-92
    CrossrefPubMedGoogle Scholar
  • 85 ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. . [Internet] Lancet 2000; 356: 2037-2044
    CrossrefPubMedGoogle Scholar
  • 86 Kastrati A, Mehilli J, Schühlen H. et al; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. [Internet] N Engl J Med 2004; 350 (03) 232-238
    CrossrefPubMedGoogle Scholar
  • 87 Kastrati A, Mehilli J, Neumann FJ. et al; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. [Internet] JAMA 2006; 295 (13) 1531-1538
    CrossrefPubMedGoogle Scholar
  • 88 Antoniucci D, Rodriguez A, Hempel A. et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. [Internet] J Am Coll Cardiol 2003; 42 (11) 1879-1885
    CrossrefPubMedGoogle Scholar
  • 89 Neumann FJ, Kastrati A, Schmitt C. et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. [Internet] J Am Coll Cardiol 2000; 35 (04) 915-921
    CrossrefPubMedGoogle Scholar
  • 90 Stone GW, Grines CL, Cox DA. et al; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. [Internet] N Engl J Med 2002; 346 (13) 957-966
    CrossrefPubMedGoogle Scholar
  • 91 Giugliano RP, White JA, Bode C. et al; EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. [Internet] N Engl J Med 2009; 360 (21) 2176-2190
    CrossrefPubMedGoogle Scholar
  • 92 Mehilli J, Kastrati A, Schulz S. et al; Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 2009; 119 (14) 1933-1940
    CrossrefPubMedGoogle Scholar
  • 93 Van't Hof AW, Ten Berg J, Heestermans T. et al; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial [Internet]. Lancet 2008; 372 (9638): 537-546
    CrossrefPubMedGoogle Scholar
  • 94 Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial. [Internet] Catheter Cardiovasc Interv 2006; 68 (02) 218-224
    CrossrefPubMedGoogle Scholar
  • 95 Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). [Internet] J Am Coll Cardiol 2007; 49 (14) 1517-1524
    CrossrefPubMedGoogle Scholar
  • 96 Ellis SG, Tendera M, de Belder MA. et al; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. [Internet] N Engl J Med 2008; 358 (21) 2205-2217
    CrossrefPubMedGoogle Scholar
  • 97 Simoons ML. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial [Internet]. Lancet 2001; 357 (9272): 1915-1924
    CrossrefPubMedGoogle Scholar
  • 98 Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. [Internet] N Engl J Med 1998; 339 (07) 436-443
    CrossrefPubMedGoogle Scholar
  • 99 Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. [Internet] N Engl J Med 1998; 338 (21) 1488-1497
    CrossrefPubMedGoogle Scholar
  • 100 Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. [Internet] N Engl J Med 1998; 338 (21) 1498-1505
    CrossrefPubMedGoogle Scholar
  • 101 Topol EJ. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial [Internet]. Lancet 2001; 357 (9272): 1905-1914
    CrossrefPubMedGoogle Scholar
  • 102 Tricoci P, Huang Z, Held C. et al; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366 (01) 20-33
    CrossrefPubMedGoogle Scholar
  • 103 Morrow DA, Braunwald E, Bonaca MP. et al; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15) 1404-1413
    CrossrefPubMedGoogle Scholar
  • 104 Knuuti J, Wijns W, Saraste A. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. [Internet] Eur Heart J 2020; 41 (03) 407-477
    CrossrefPubMedGoogle Scholar
  • 105 Collet JP, Thiele H, Barbato E. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. [Internet] Eur Heart J 2021; 42 (14) 1289-1367
    CrossrefPubMedGoogle Scholar
  • 106 Neumann F-J, Sousa-Uva M, Ahlsson A. et al; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40 (02) 87-165
    CrossrefPubMedGoogle Scholar
  • 107 Ibanez B, James S, Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. . [Internet] Eur Heart J 2018; 39: 119-177
    CrossrefPubMedGoogle Scholar
  • 108 Chen ZM, Jiang LX, Chen YP. et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial [Internet]. Lancet 2005; 366 (9497): 1607-1621
    CrossrefPubMedGoogle Scholar
  • 109 Schulz-Schüpke S, Byrne RA, Ten Berg JM. et al; Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. [Internet] Eur Heart J 2015; 36 (20) 1252-1263
    CrossrefPubMedGoogle Scholar
  • 110 Valgimigli M, Campo G, Monti M. et al; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. [Internet] Circulation 2012; 125 (16) 2015-2026
    CrossrefPubMedGoogle Scholar
  • 111 Hahn J-Y, Song YB, Oh JH. et al; SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 2019; 321 (24) 2428-2437
    CrossrefPubMedGoogle Scholar
  • 112 Valgimigli M, Frigoli E, Heg D. et al; MASTER DAPT Investigators. Dual antiplatelet therapy after PCI in patients at high bleeding risk. [Internet] N Engl J Med 2021; 385 (18) 1643-1655
    CrossrefPubMedGoogle Scholar
  • 113 Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. . [Internet] Lancet 2001; 358: 605-613
    CrossrefPubMedGoogle Scholar